JP2025508835A - アラーミンに対する二重特異性結合タンパク質およびその使用 - Google Patents

アラーミンに対する二重特異性結合タンパク質およびその使用 Download PDF

Info

Publication number
JP2025508835A
JP2025508835A JP2024550197A JP2024550197A JP2025508835A JP 2025508835 A JP2025508835 A JP 2025508835A JP 2024550197 A JP2024550197 A JP 2024550197A JP 2024550197 A JP2024550197 A JP 2024550197A JP 2025508835 A JP2025508835 A JP 2025508835A
Authority
JP
Japan
Prior art keywords
antibody
bispecific binding
seq
binding protein
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024550197A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025508835A5 (https=
Inventor
ナン ソン
リク ハン ラム
チン ワイ ホイ
ウェイミン リー
シュイ オン レオン
Original Assignee
シノマブ バイオサイエンス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シノマブ バイオサイエンス リミテッド filed Critical シノマブ バイオサイエンス リミテッド
Publication of JP2025508835A publication Critical patent/JP2025508835A/ja
Publication of JP2025508835A5 publication Critical patent/JP2025508835A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2024550197A 2022-02-24 2023-02-23 アラーミンに対する二重特異性結合タンパク質およびその使用 Pending JP2025508835A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263313483P 2022-02-24 2022-02-24
US63/313,483 2022-02-24
PCT/CN2023/077870 WO2023160610A1 (en) 2022-02-24 2023-02-23 Bispecific binding proteins against alarmins and uses thereof

Publications (2)

Publication Number Publication Date
JP2025508835A true JP2025508835A (ja) 2025-04-10
JP2025508835A5 JP2025508835A5 (https=) 2026-02-27

Family

ID=87764833

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024550197A Pending JP2025508835A (ja) 2022-02-24 2023-02-23 アラーミンに対する二重特異性結合タンパク質およびその使用

Country Status (11)

Country Link
US (1) US20240409647A1 (https=)
EP (1) EP4482525A1 (https=)
JP (1) JP2025508835A (https=)
KR (1) KR20240161653A (https=)
CN (1) CN119183384A (https=)
AU (1) AU2023223413A1 (https=)
CA (1) CA3253236A1 (https=)
CL (1) CL2024002512A1 (https=)
IL (1) IL315208A (https=)
MX (1) MX2024010459A (https=)
WO (1) WO2023160610A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025118126A1 (zh) * 2023-12-05 2025-06-12 中国抗体制药有限公司 抗il-17rb抗体、或其抗原结合片段或组合物的用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
AU582288B2 (en) 1986-03-07 1989-03-16 Damon Biotech Inc. Vector and method for achieving high level expression in eukaryotic cells
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US9090694B2 (en) * 2012-04-30 2015-07-28 Janssen Biotech, Inc. ST2L antibody antagonists
US9840557B2 (en) * 2014-09-23 2017-12-12 Regeneron Pharmaceuticals, Inc. Anti-IL-25 antibodies and uses thereof
MX2018013038A (es) * 2016-04-27 2019-03-28 Pfizer Anticuerpos anti-il-33, composiciones, metodos y usos de los mismos.
GB201820006D0 (en) 2018-12-07 2019-01-23 Lifearc Humanised anti-IL17BR antibody
PE20230252A1 (es) * 2020-03-13 2023-02-07 Genentech Inc Anticuerpos anti-interleucina-33 y sus usos de estos
GB202018015D0 (en) * 2020-11-16 2020-12-30 Res & Innovation Uk Composition and methods for the treatment of intestinal cancer

Also Published As

Publication number Publication date
WO2023160610A1 (en) 2023-08-31
KR20240161653A (ko) 2024-11-12
MX2024010459A (es) 2024-11-08
CL2024002512A1 (es) 2024-11-22
CA3253236A1 (en) 2023-08-31
AU2023223413A1 (en) 2024-10-10
IL315208A (en) 2024-10-01
US20240409647A1 (en) 2024-12-12
EP4482525A1 (en) 2025-01-01
CN119183384A (zh) 2024-12-24

Similar Documents

Publication Publication Date Title
US20250154241A1 (en) Antigen binding proteins capable of binding thymic stromal lymphopoietin
TWI853077B (zh) 新型抗ｃｄ３９抗體
JP6445596B2 (ja) 抗ｉｌ−２３抗体
EP4289861A1 (en) Antibodies against human tslp and use thereof
CA2959551C (en) Anti-tnf-/anti-il-23 bispecific antibodies
JP6931750B2 (ja) 抗ｉｌ−１７ａ／ｆ抗体を用いた治療方法
EP4286011A2 (en) Fcrn antibodies and methods of use thereof
KR102840867B1 (ko) 치료용 항-cd40 리간드 항체
JP2016539638A (ja) 腫瘍壊死因子様リガンド１ａ特異的抗体ならびにその組成物および使用
EP3632932A1 (en) Anti-cd40 antibody, antigen binding fragment thereof and medical use thereof
CN106459217A (zh) 多特异性抗体构建体
CN108473568A (zh) 对TNF-α、IL-17A和IL-17F具有特异性的多特异性抗体分子
JP2026050475A (ja) 抗ｐａｒ－２抗体及びそれらの使用方法
US20240409647A1 (en) Bispecific binding proteins against alarmins and uses thereof
TW202216198A (zh) 使用抗組織因子抗體之炎性疾病治療
HK40120136A (zh) 针对警报素的双特异性结合蛋白及其用途
KR20180089521A (ko) Tnf 알파에 결합하는 항체 분자
JP7603061B2 (ja) Ｃｒ２結合タンパク質および医学的治療におけるそれらの使用
HK40103769A (en) Fcrn antibodies and methods of use thereof
KR20260025131A (ko) 림포톡신 베타 수용체 작용제 결합 단백질
HK1247218A1 (en) Fcrn antibodies and methods of use thereof
HK1187627A1 (zh) 4-1bb结合分子

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260218

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260218